Looking back on 2024, it has been a year of remarkable progress for Fosun.

Ten events have defined Fosun’s journey this year, telling a story of relentless pursuit.

We ignited hope with cures, embraced passion with enthusiasm, allowed time to unveil answers, and illuminated the future with wisdom.

As we approach 2025, we catch a glimpse of light, filling us with anticipation for the future.

01 Globalization

Fosun’s biosimilars made their overseas debut, benefiting over 600,000 patients worldwide

In November, Shanghai Henlius’ HANQUYOU made its first shipment to the U.S., marking the company's first commercial supply to North America. With this shipment, Shanghai Henlius has realized the commercial supply of its products to regions including China, Southeast Asia, North America, Europe, the Middle East, and Latin America. Currently, Shanghai Henlius has six products launched in China and three products launched globally. Earlier this year, in April, HANQUYOU became the first China-developed monoclonal antibody biosimilar approved in China, the U.S., and the EU. To date, it has been approved for marketing in 50 countries and regions and included in the catalog of medicines covered by national medical insurance in China, the UK, France, Germany, etc. In the first half of 2024, HANQUYOU generated sales revenue of approximately RMB1.474 billion. Another flagship product, the independently developed anti-PD-1 monoclonal antibody, HANSIZHUANG, was shipped to Indonesia in January, marking the first China-developed anti-PD-1 monoclonal antibody approved for marketing in Southeast Asia. It has been out-licensed to over 70 countries and regions.

On 29 November, the shipment of HANQUYOU departed from Shanghai Henlius’ Songjiang  Plant, heading to the U.S.

On 25 January, HANSIZHUANG was dispatched from Shanghai Henlius’ Songjiang Plant to Indonesia.

02 Innovation-driven

Fosun’s integrated innovation fuels collaborative success with the launch of the Ion System in China

In June, the Intuitive Fosun Headquarters Industrial Base officially opened in Shanghai. With a total investment of approximately RMB700 million, this facility is the largest integrated R&D, production, and training base of Intuitive Surgical in the Asia-Pacific region and the second global R&D and manufacturing base of the da Vinci Surgical Systems in addition to the base in Silicon Valley, the U.S. Its launch has significantly accelerated the domestic manufacturing of the da Vinci Surgical Systems in Chinese mainland. Another flagship product of Intuitive Fosun, the Ion Bronchial Navigation Operation Control System (Ion System), was approved for marketing by the National Medical Products Administration (NMPA) this year. In September, the first commercial installation was completed at Shanghai Chest Hospital and the first procedure was performed at the Affiliated Hospital of Xuzhou Medical University. By focusing on global demand through integrated innovation, Fosun is unlocking greater value and promoting collaborative success.

On 12 September, the first national procedure using the Ion Bronchial Navigation Operation Control System (Ion System) was successfully performed at the Affiliated Hospital of Xuzhou Medical University

On 12 June, Intuitive Fosun Headquarters Industrial Base officially opened in Shanghai

03  Innovation-driven

Fosun’s CAR-T cell therapy platform was restructured, with Fosun Kairos igniting hope for cures

On 13 September, Fosun Pharma completed a full acquisition of Fosun Kite, renaming it as Fosun Kairos. Fosun Kairos’ CAR-T cell therapy product, Yi Kai Da, is the first and currently the only CAR-T cell therapy approved for second-line indication in Chinese mainland. To date, Fosun Kairos has established over 170 high-standard treatment centers across 28 provinces and cities in China. Yi Kai Da has also been included into more than 110 urban customized commercial health insurances and over 80 commercial insurances. Moreover, it introduced an innovative payment plan based on therapeutic effects, opening up a new path for the payment mode of high-value first-in-class drugs in China. Following the restructure, Fosun Kairos will serve as the core platform for Fosun Pharma's cell therapy technologies, concentrating on tumor immunotherapy to enhance access to CAR-T cell therapies for more patients and offer them more hope for cures.

Yi Kai Da, the first CAR-T cell therapy product approved for marketing in Chinese mainland, has been used to treat over 900 lymphoma patients since its launch

04  Globalization

Fosun’s decade-long journey of globalization in Portugal – from investment to win-win

This year marks the 45th anniversary of diplomatic relations between China and Portugal, as well as the tenth year of Fosun's deep engagement in the Portuguese market. Since the acquisition of Fidelidade in 2014, Fosun has grown into the Chinese private enterprise with the largest investment in Portugal. Its investment includes Fidelidade (Fosun Insurance Portugal, Portugal's largest insurance company), Luz Saúde (one of the largest healthcare groups), and Millennium BCP (Portugal's largest listed privately-owned bank). Fosun has supported the local operations of these enterprises and facilitated their rapid expansion into international markets, particularly in Portuguese-and-Spanish-speaking countries, as well as rapid growth in Latin America and Africa. Alongside business success, Fosun and Fidelidade have gained widespread recognition and established a positive reputation for their contributions to local communities. Today, Portugal serves as a critical gateway for Fosun’s engagement with Spanish and Portuguese-speaking countries. Fosun’s journey in Portugal shows that Chinese enterprises can be more than just opportunity-driven players, they can also create lasting value.

Fidelidade’s headquarters in Lisbon, Portugal

Luz Saúde’s flagship hospital in Lisbon is one of the largest and most advanced private hospitals in Portugal, and it is the only hospital in Lisbon offering consultations in Chinese

05 Globalization

Fosun expanded global footprint in emerging markets in the Middle East

In September, Hainan Mining made a full tender offer to acquire Tethys Oil AB, securing oil field rights in several blocks in Oman. This significant move follows a memorandum of understanding signed in July between Hainan Mining and Ajlan & Bros Holding, marking another major strategic initiative for Hainan Mining in the Middle East. In the pharmaceutical sector, Shanghai Henlius entered into a strategic collaboration with AL-TIRYAQ AL-KHALAWI Medical Company (SVAX) to establish joint ventures in Saudi Arabia, seeking to advance the global registration and commercialization of Shanghai Henlius’ products. Since the beginning of this year, Fosun has actively explored emerging markets in the Middle East, enhancing its globalization capabilities and expanding its global footprint.

On 7 November, Shanghai Henlius and AL-TIRYAQ AL-KHALAWI Medical Company (SVAX) signed a strategic collaboration agreement at the 7th China International Import Expo (CIIE)

On 16 July, Hainan Mining signed a memorandum of understanding with Ajlan & Bros Holding

06 Innovation-driven

Fosun Pharma celebrated 30 years of original innovation, ready to embark on a new journey!

On 17 November, the 2nd Pujiang Biopharmaceutical Original Innovation Forum was held. As the organizer of the Forum, Fosun Pharma has consistently focused on the original innovation of biopharmaceuticals. This year marks Fosun Pharma’s 30th anniversary. Driven by innovation, Fosun Pharma has focused on patient needs over the past 30 years. It has developed innovative products targeting core therapeutic areas such as oncology, autoimmunity, central nervous system, and chronic disease, and has achieved numerous “world's first” and “China's first" innovations. Its products including HANLIKANG, China’s first independently developed biosimilar, HANQUYOU, China’s first independently developed biosimilar approved in China, the U.S., and EU, and HANSIZHUANG, the world’s first anti-PD-1 monoclonal antibody approved for first-line treatment of small cell lung cancer, have benefited millions of patients.

Fosun Pharma embraces an open mindset to foster collaborative innovation. Recent achievements include the domestic manufacturing of the da Vinci Surgical Systems, the commercialization of the Ion System in China, and Yi Kai Da becoming the first CAR-T cell therapy product approved in China, and artesunate for injection contributing China's innovative solution for the global fight against malaria.  These achievements of successive “bring in” and “go global” initiatives reflect Fosun’s commitment to advancing Chinese biopharmaceuticals on the global stage.

Fosun Pharma signed strategic collaboration agreements with Shanghai Guangci Translational Medical Research Foundation, Fudan University, Shanghai University, Ruijin Hospital, Shanghai Institute of Materia Medica, Chinese Academy of Sciences and other institutions at the 2nd Pujiang Biopharmaceutical Original Innovation Forum

Fosun management and Fosun Pharma staff jointly celebrated the 30th anniversary of Fosun Pharma

07 Household Consumption

Flagship projects redefine China’s cultural tourism landscape

On 30 October, the ULTRAMED Hainan project was officially launched. As a new landmark project launched by Fosun,  the ULTRAMED Hainan aims to create the world’s first AI-themed resort and form a super tourism cluster together with Atlantis Sanya. In addition, Fosun is making strides in ice and snow tourism. In June, the Taicang Alps Resort phase II project was signed, which is set to become the largest indoor skiing facility globally. It will feature a ski resort, water park, land park, and hot springs. Another flagship brand, Club Med, opened Club Med Joyview Heilongtan this year and announced a collaboration with Dapeng New District in Shenzhen and CITIC to establish the first Club Med resort in the Greater Bay Area.

On 30 October, the ULTRAMED Hainan project was officially launched, creating the world's first AI-themed resort

On 18 June, the Taicang Alps Resort phase II project was signed

08 Household Consumption

Yuyuan Garden Lantern Festival celebrates its 30th anniversary and shines overseas once again

On 1 January 2025, the Yuyuan Garden Lantern Festival will light up Shanghai, continuing the story of "Wonders of Mountains and Seas" under the theme of "Everything is Wonderful, All Beings are Amazing." The year marks its 30th anniversary, with celebrations extending to cities such as Hainan, Shenyang, and Sichuan. A special exhibition titled "Beyond Lanterns” - The 30th Anniversary of Yuyuan Lantern Festival and China Lantern Exhibition will also be staged to mark this special occasion. In addition, the Yuyuan Garden Lantern Festival will take place in Thailand in 2025, marking its second international event following its successful debut in France. Coinciding with the 50th anniversary of diplomatic relations between China and Thailand, this event will feature a spectacular blend of traditional Chinese lanterns and modern light technology, showcasing the richness and unique charm of Chinese culture. It not only serves as a special gift for the people of both nations, but also a strong testament to the friendship between China and Thailand.

Visitors are taking a selfie with the lantern display on Ninghui Road, Yuyuan Garden.

09 Credit Rating

Fosun returned to the USD bond market with improved creditworthiness

In November, Fosun International successfully issued a USD300 million 3.5-year US-dollar-denominated senior unsecured notes, marking its return to the USD bond market after three years. International credit rating agency, S&P, released a report highlighting that the successful issuance helped broaden Fosun’s funding channels. It also maintained a “stable” outlook on Fosun International’s rating. At the end of September, Fosun International announced the closure of a sustainability-linked syndicated loan totaling USD888 million through greenshoe. The continued recognition of Fosun's credit quality by both domestic and international banks reflects the company’s sound financing channels and effective liquidity management, providing a solid foundation for its steady development.

The Bund Finance Center (BFC) hosted a Christmas lighting ceremony to celebrate its 5th anniversary during the 2024 holiday season

10 Contribution to Society

Fosun continues to create IMPACT with the Rural Doctors Program recognized in UNGC's "20 Cases of Private Sector's Sustainable Development in China for 20 Years" report

On 29 November, the United Nations Global Compact (UNGC) held a launch event for the “20 Cases of Private Sector’s Sustainable Development in China for 20 Years.” Fosun’s “Rural Doctors Program Empowering Rural Medical Services” was recognized as one of the selected cases in the report. This year marks Fosun’s 10th anniversary as a UNGC member. Since joining, Fosun has integrated the ten principles of the UN Global Compact on human rights, labor, environment and anticorruption into its corporate strategy and operations, achieving an MSCI ESG rating of AA for three consecutive years. This year, Fosun has formulated the sustainable development strategy: “Create IMPACT” and identified six major long-term strategic directions to actively promote global sustainable development.

Rural doctor Yang Fen is conducting a health check-up on a child